Jayanthi Padmanabhan
Overview
Explore the profile of Jayanthi Padmanabhan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen V, Welsh J, Tertel T, Choo A, van de Wakker S, Defourny K, et al.
J Extracell Vesicles
. 2024 Jun;
13(6):e12463.
PMID: 38868945
Mesenchymal stromal cells (MSCs) are promising regenerative therapeutics that primarily exert their effects through secreted extracellular vesicles (EVs). These EVs - being small and non-living - are easier to handle...
2.
Tan T, Lai R, Padmanabhan J, Sim W, Choo A, Lim S
Pharmaceuticals (Basel)
. 2021 Apr;
14(4).
PMID: 33918628
Mesenchymal-stem/stromal-cell-derived small extracellular vesicles (MSC-sEV) have been shown to ameliorate many diseases in preclinical studies. However, translating MSC-sEV into clinical use requires the development of scalable manufacturing processes for highly...
3.
Tan H, Yong C, Tan B, Fong W, Padmanabhan J, Chin A, et al.
Sci Rep
. 2018 Aug;
8(1):11608.
PMID: 30072783
Monoclonal antibodies (mAbs) are used as targeted therapies against cancers. These mAbs kill cancer cells via various mechanisms of actions. In this study, human embryonic stem cells (hESCs) was used...
4.
Lai R, Yeo R, Padmanabhan J, Choo A, de Kleijn D, Lim S
Methods Mol Biol
. 2016 May;
1416:477-94.
PMID: 27236691
Mesenchymal stem cells (MSC) are currently the cell type of choice in many cell therapy trials. The number of therapeutic applications for MSCs registered as product IND submissions with the...
5.
Leung H, Moerkamp A, Padmanabhan J, Ng S, Goumans M, Choo A
J Mol Cell Cardiol
. 2015 Mar;
82:228-37.
PMID: 25820071
Aims: Cardiac progenitor cells (CPCs) have been isolated from adult and developing hearts using an anti-mouse Sca-1 antibody. However, the absence of a human Sca-1 homologue has hampered the clinical...
6.
Chen T, Arslan F, Yin Y, Tan S, Lai R, Choo A, et al.
J Transl Med
. 2011 Apr;
9:47.
PMID: 21513579
Background: Exosomes or secreted bi-lipid vesicles from human ESC-derived mesenchymal stem cells (hESC-MSCs) have been shown to reduce myocardial ischemia/reperfusion injury in animal models. However, as hESC-MSCs are not infinitely...
7.
Chin A, Padmanabhan J, Oh S, Choo A
Stem Cells Dev
. 2009 Aug;
19(6):753-61.
PMID: 19686051
Four commercially available serum-free and defined culture media tested on 2 human embryonic stem cell (hESC) lines were all found to support undifferentiated growth for >10 continuous passages. For hESC...
8.
Choo A, Padmanabhan J, Chin A, Fong W, Oh S
J Biotechnol
. 2005 Oct;
122(1):130-41.
PMID: 16233925
Human embryonic stem cells (hESC) are pluripotent cells that proliferate indefinitely in culture, whilst retaining their capacity for differentiation into different cell types. However, hESC cultures require culture in direct...
9.
Oh S, Fong W, Teo Y, Tan H, Padmanabhan J, Chin A, et al.
Biotechnol Bioeng
. 2005 Jul;
91(5):523-33.
PMID: 16044469
Embryonic stem cells (ESC) have the unique ability to differentiate into a variety of tissue types. However, the realization of regenerative medicine will require the production of large quantities of...
10.
Choo A, Padmanabhan J, Chin A, Oh S
Biotechnol Bioeng
. 2004 Oct;
88(3):321-31.
PMID: 15486939
Human embryonic stem cells (HES) hold great potential for regenerative medicine because of their ability to differentiate to any cell type. However, a limitation is that HES cells require a...